

# Celiac disease microbiota and its applications

Iulia Lupan · Genel Sur · Diana Deleanu ·  
Victor Cristea · Gabriel Samasca · Peter Makovicky

Received: 14 May 2013 / Accepted: 2 December 2013 / Published online: 14 December 2013  
© Springer-Verlag Berlin Heidelberg and the University of Milan 2013

**Abstract** Intestinal microbiota plays an important role in maintaining the overall health of an individual. It can be affected by diet but also inflammation of the intestine due to various causes. In the last decade, particular attention has been paid to the study of the interaction between mucosal cells and intestinal microbiota, and to the host immune response to change in community structure. Here, we review the most significant studies on human microbiota in patients with celiac disease, and also the potential biotechnological use of microorganisms for the production of gluten-free products.

**Keywords** Adolescence · Gluten-free · Microbiology · Sorghum

## Introduction

Most microorganisms in the human microbiota are in the intestine. The intestinal microbiota plays an important role in metabolic and nutritional processes, but also has a defensive

role in assuring intestinal health. In recent years, special attention has been paid to studying the intestinal microbiota in intestinal disease, as well as changes in the microbiota with dietary variations and with age.

An important therapeutic strategy for many mucosal and non-mucosal immune-related conditions is to harness the skill of microbiota to disturb host immunity (Ivanov and Honda 2012). Alterations in microbial flora accompany various medical conditions (Serban 2011), such as inflammatory bowel diseases and celiac disease (CD). The intestinal microbiota also changes substantially during aging (Cheng et al. 2011). This review discusses important recent discoveries regarding microbiota in relation to gluten-free diet (GFD) in patients with CD.

## Celiac disease

### Immunopathological state of CD

Under immunopathological conditions, e.g., during infection, inflammatory bowel disease and CD, both epithelial cells and intraepithelial lymphocytes participate substantially in inflammatory reactions (Tlaskalová-Hogenová et al. 1995). Intestinal microbiota influence the Th1 pro-inflammatory milieu characteristic of CD (Medina et al. 2008). Serological responses to different microbial antigens have been demonstrated (Ashorn et al. 2009). Persons with selective IgA deficiency carry an increased risk of CD. The microbiota of IgA-deficient people is characterized by an increased frequency of *Escherichia coli* with inflammogenic potential, and can thus contribute to the development of inflammatory bowel diseases (Friman et al. 2002). A reduction in IgA-coated bacteria is associated with intestinal dysbiosis, providing new insights into the possible relationships between gut microbiota and host defences in CD patients (De Palma et al. 2010).

---

I. Lupan  
Molecular Biology Center, Institute for Interdisciplinary Research on Bio-Nano-Sciences, Babes-Bolyai University,  
Cluj-Napoca, Romania

G. Sur  
Department of Pediatrics II, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

D. Deleanu · V. Cristea · G. Samasca (✉)  
Department of Immunology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Croitorilor Street, 19-21 No,  
Cluj-Napoca, Romania  
e-mail: Gabriel.Samasca@umfcluj.ro

P. Makovicky  
Department of Veterinary Science, Czech University of Life Science, Prague, Czech Republic

## Celiac disease studies

CD patients with intestinal enzymopathy have, in general, diminished protective flora and increased hemolytic and lactose-negative enterobacteria (Kamilova et al. 2001). The levels of *Bacteroides*, *Clostridium* and *Staphylococcus* were much higher ( $P < 0.05$ ) in fecal samples from CD patients than in those of healthy subjects when analyzed by culture methods (Collado et al. 2007). The species *Lactobacillus curvatus*, *Leuconostoc mesenteroides* and *Leuconostoc carnosum* were characteristic of CD patients, while those of the *Lactobacillus casei* group were characteristic of healthy controls (Sanz et al. 2007).

Analysis of fecal samples and duodenal biopsies using denaturing gradient gel electrophoresis specific for total bacteria, lactobacilli and bifidobacteria the microbial population showed that bacteria adhering to duodenal biopsies were not dominating in stool samples (Kopečný et al. 2008). A peculiar microbial temporal temperature gradient gel electrophoresis profile and a significant higher biodiversity were identified in the duodenal mucosa of CD pediatric patients. *Bacteroides vulgatus* and *E. coli* were detected more often in CD patients than in controls ( $P < 0.0001$ ) (Schippa et al. 2010). Thus, virulence features of the enteric microbiota are linked to CD (Sánchez et al. 2008).

Examination of differences in *Bacteroides* spp. and their pathogenic features between CD patients and controls revealed an increased abundance of *Bacteroides fragilis* strains with metalloprotease activities, which could play a role in CD pathogenesis (Sánchez et al. 2012a). Two novel, obligately anaerobic, Gram-stain-positive, saccharolytic and non-proteolytic spore-forming bacilli [strains CD3:22(T) and N1 (T)] were described. One of them, strain CD3:22(T) was isolated from a biopsy of the small intestine of a child with CD (Hedberg et al. 2012).

## Active and non-active celiac disease

The proportions of total bacteria and Gram-negative bacteria were much higher in CD patients with active disease than in symptom-free CD patients and controls (Nadal et al. 2007). Reductions in total *Bifidobacterium* and *Bacteroides longum* populations were associated with both active and non-active CD when compared to controls (Collado et al. 2008). *Bacteroides*, *Bifidobacterium* and lactic acid bacteria (LAB) populations in the duodenum of children with typical CD (active and treated) and controls differ in diversity and species composition; this could help illustrate features of the disease (Sánchez et al. 2010). Increased abundance of *Staphylococcus epidermidis* carrying the *mecA* gene in active and non-active CD patients most likely reflects increased exposure of these subjects to opportunistic pathogens and antimicrobials (Sánchez et al. 2012b).

## Clinical implications

Cesarean delivery can affect the early biodiversity of intestinal bacteria (Biasucci et al. 2008). An association was described between cesarean delivery and CD. Alterations of the mucosal host-microbial interaction during the neonatal period might contribute to the pathogenesis of inflammatory diseases such as CD (Decker et al. 2011).

Breast milk is the gold-standard feeding method during infancy for optimal nutrition (Salvatore et al. 2008). But milk-feeding type can also play a role in CD (Sanz et al. 2011). The effects of milk-feeding practices on intestinal colonization of *Bacteroides* species in infants at risk of CD development was investigated. Breast-fed infants showed a higher prevalence of *Bacteroides uniformis* at 1 and 4 months of age, while formula-fed infants had a higher prevalence of *Bacteroides intestinalis* at all sampling times, of *Bacteroides caccae* at 7 days and 4 months, and of *Bacteroides plebeius* at 4 months. The conclusion was that both the type of milk feeding influences the colonization process of *Bacteroides* species, and possibly disease risk (Sánchez et al. 2011). Another study came to a similar conclusion, i.e., that milk-feeding type plays a role in establishing infants' gut microbiota (De Palma et al. 2012).

## Gluten-free diet

### Gluten-free diet and CD

The accepted treatment for CD is a gluten-free diet (GFD) (Samaşca et al. 2013). However, GFD influences the structure of the gut bacterial population and its metabolism markedly (Kopečný et al. 2006). GFD has been shown to lead to reductions in beneficial gut bacteria populations and stimulate the host's immunity (De Palma et al. 2009). The analysis of fecal microbiota and dietary intake after GFD indicated that the numbers of healthy gut bacteria decreased, while numbers of unhealthy bacteria increased parallel to reductions in the intake of polysaccharides in CD adults (Sanz 2010). In conclusion, there are bacterial differences in the upper small bacteria microbiota between treated and untreated CD adults due to treatment with a GFD (Nistal et al. 2012). Duodenal and fecal microbiotas are unbalanced in children with untreated CD and only partially restored after long-term treatment with GFD (Collado et al. 2009). A lower ratio of cultivable LAB and *Bifidobacterium* to *Bacteroides* and enterobacteria in CD children after GFD compared to healthy children was observed—even lower in CD children before GFD (Di Cagno et al. 2009). Therefore, GFD lasting at least 2 years did not completely restore the microbiota and, thus, the metabolome of CD children (Di Cagno et al. 2011). So what are the solutions?

## Plant extract solutions

The crude water-soluble extract from amaranth seeds has an inhibitory effect towards many fungal species isolated from bakeries and is used as an ingredient in the manufacture of gluten-free (GF) and wheat bread (Rizzello et al. 2009), extending the shelf-life of gluten-free and wheat flour breads. The alcohol-soluble fraction from some cereals (tef, millet, amaranth, and quinoa) has been shown to be safe for diets of CD patients, with the absence of any immune cross-reactivity of them toward wheat gliadin being of note (Bergamo et al. 2011). The aqueous extract of kiwifruit puree, which has good stability and contains polyphenols and antioxidants, was also considered as a functional ingredient for GF bread (Sun-Waterhouse et al. 2009). But the replacement of gluten still presents a significant technological challenge, as it is an essential structure-building protein necessary for formulating high-quality baked goods (Zannini et al. 2012a).

## Sourdough biotechnologies

Sourdough has been used since ancient times for the production of rye and wheat bread; its universal usage has been attributed to the improved quality, nutritional properties and shelf life of sourdough-based breads (Arendt et al. 2011). Producing sourdough bread that is tolerated by CD patients has been an important focus for many researchers (Di Cagno et al. 2004) with biotechnologies that use selected sourdough LAB and probiotics and their potential to decrease the risk of gluten contamination in gluten-free products being investigated (Gobbetti et al. 2007).

*Lactobacillus plantarum* CRL 759 and CRL 778 have an active proteolytic system that is responsible for high amino acid release during sourdough fermentation and the hydrolysis of 31–43 alpha-gliadin-like fragments (Rollán et al. 2005). The kinetics of the hydrolysis of this 33-mer by lactobacilli were highly efficient (Rizzello et al. 2007). The ability of LAB strains to degrade alpha-gliadin fragments is not correlated to individual peptidase activities. Results have shown that several strains separately degraded 31–43 and 62–75 alpha-gliadin fragments, while a mixture of peptidase profiles from pooled LAB strains was associated with 57–89 peptide degradation (Gerez et al. 2008). Other studies supported the same conclusion. The use of sourdough in GF baking was suggested as a new frontier for increasing the quality, safety and acceptability of GF bread (Moroni et al. 2009).

The use of a pool of selected enterococci and fungal proteases (*Rhizopus oryzae*) to hydrolyze wheat gluten during long-duration fermentation was investigated. This microbial and protein cocktail showed a decrease in the gluten concentration of more than 98 % during longer fermentation (M'hir et al. 2009). The biodiversity of spontaneous environmental biota from buckwheat and teff sourdoughs showed a broad

spectrum of yeast species and LAB. The selection of dominant yeast and *Lactobacillus* species as starters for the production of sourdough destined for GF bread production was suggested (Moroni et al. 2011). Another promising approach to improve bread-making for GFD can be to manipulate microbial exopolysaccharide amounts to reach effectual levels through optimization, as corroborated by the application of microbial exopolysaccharide-forming starter cultures (Rühmkorf et al. 2012; Galle et al. 2012). The use of two lactic bacteria (*Lactobacillus plantarum* CRL 775 and *Pediococcus pentosaceus* CRL 792) as cell free extract and pooled cells showed a higher efficiency of cell extracts in the reduction of gliadin concentration, thus use of cell-free extract may be considered a practical alternative technology for the manufacture of GF products (Gerez et al. 2012). Microbial fermentation by LAB and yeast is considered one of the most ecological/economical methods of producing and preserving food (Zannini et al. 2012b).

## Conclusions

The role of intestinal microbial flora in certain pathologies such as CD currently remains unknown. Most studies in this area have revealed changes in gut microbiota but not their role in the evolution of CD pathology. Bacterial species other than those present in healthy subjects prevail in the intestinal microbiota of patients with CD. The most effective treatment in CD, i.e., GFD, does not contribute to restoring of the intestinal microbiota, with the observed imbalance being maintained even after treatment. Meanwhile, microbial biotechnology can provide solutions for making gluten-free products.

**Conflict of interest** The authors report no conflicts of interest.

## References

- Arendt EK, Moroni A, Zannini E (2011) Medical nutrition therapy: use of sourdough lactic acid bacteria as a cell factory for delivering functional biomolecules and food ingredients in gluten free bread. *Microb Cell Fact* 10:S15
- Ashorn S, Välineva T, Kaukinen K, Ashorn M, Braun J, Raukola H, Rantala I, Collin P, Mäki M, Luukkaala T, Iltanen S (2009) Serological responses to microbial antigens in celiac disease patients during a gluten-free diet. *J Clin Immunol* 29:190–195
- Bergamo P, Maurano F, Mazzarella G, Iaquinto G, Vocca I, Rivelli AR, De Falco E, Gianfrani C, Rossi M (2011) Immunological evaluation of the alcohol-soluble protein fraction from gluten-free grains in relation to celiac disease. *Mol Nutr Food Res* 55:1266–1270
- Biasucci G, Benenati B, Morelli L, Bessi E, Boehm G (2008) Cesarean delivery may affect the early biodiversity of intestinal bacteria. *J Nutr* 138:1796S–1800S

- Cheng J, Palva AM, de Vos WM, Satokari R (2011) Contribution of the Intestinal Microbiota to Human Health: From Birth to 100 Years of Age. *Curr Top Microbiol Immunol* 358:323–346. doi:10.1007/82\_2011\_189
- Collado MC, Calabuig M, Sanz Y (2007) Differences between the fecal microbiota of coeliac infants and healthy controls. *Curr Issues Intest Microbiol* 8:9–14
- Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2008) Imbalances in faecal and duodenal *Bifidobacterium* species composition in active and non-active coeliac disease. *BMC Microbiol* 8:232
- Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2009) Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. *J Clin Pathol* 62:264–269
- De Palma G, Nadal I, Collado MC, Sanz Y (2009) Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects. *Br J Nutr* 102:1154–1160
- De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2010) Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. *BMC Microbiol* 10:63
- De Palma G, Capilla A, Nova E, Castillejo G, Varea V, Pozo T, Garrote JA, Polanco I, López A, Ribes-Koninckx C, Marcos A, García-Novo MD, Calvo C, Ortigosa L, Peña-Quintana L, Palau F, Sanz Y (2012) Influence of milk-feeding type and genetic risk of developing coeliac disease on intestinal microbiota of infants: the PROFICEL study. *PLoS One* 7:e30791
- Decker E, Hornef M, Stockinger S (2011) Cesarean delivery is associated with coeliac disease but not inflammatory bowel disease in children. *Gut Microbes* 2:91–98
- Di Cagno R, De Angelis M, Auricchio S, Greco L, Clarke C, De Vincenzi M, Giovannini C, D'Archivio M, Landolfo F, Parrilli G, Minervini F, Arendt E, Gobbetti M (2004) Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in coeliac sprue patients. *Appl Environ Microbiol* 70:1088–1096
- Di Cagno R, Rizzello CG, Gagliardi F, Ricciuti P, Ndagijimana M, Francavilla R, Guerzoni ME, Crecchio C, Gobbetti M, De Angelis M (2009) Different fecal microbiotas and volatile organic compounds in treated and untreated children with coeliac disease. *Appl Environ Microbiol* 75:3963–3971
- Di Cagno R, De Angelis M, De Pasquale I, Ndagijimana M, Vernocchi P, Ricciuti P, Gagliardi F, Laghi L, Crecchio C, Guerzoni ME, Gobbetti M, Francavilla R (2011) Duodenal and faecal microbiota of coeliac children: molecular, phenotype and metabolome characterization. *BMC Microbiol* 11:219
- Friman V, Nowrouzian F, Adlerberth I, Wold AE (2002) Increased frequency of intestinal *Escherichia coli* carrying genes for *S. fimbriae* and haemolysin in IgA-deficient individuals. *Microb Pathog* 32:35–42
- Galle S, Schwab C, Dal Bello F, Coffey A, Gänzle MG, Arendt EK (2012) Influence of in-situ synthesized exopolysaccharides on the quality of gluten-free sorghum sourdough bread. *Int J Food Microbiol* 155:105–112
- Gerez CL, Font de Valdez G, Rollán GC (2008) Functionality of lactic acid bacteria peptidase activities in the hydrolysis of gliadin-like fragments. *Lett Appl Microbiol* 47:427–432
- Gerez CL, Dallagnol A, Rollán G, Font de Valdez G (2012) A combination of two lactic acid bacteria improves the hydrolysis of gliadin during wheat dough fermentation. *Food Microbiol* 32:427–430
- Gobbetti M, Rizzello CG, Di Cagno R, De Angelis M (2007) Sourdough lactobacilli and coeliac disease. *Food Microbiol* 24:187–196
- Hedberg ME, Moore ER, Svensson-Stadler L, Hörstedt P, Baranov V, Hemell O, Wai SN, Hammarström S, Hammarström ML (2012) *Lachnoanaerobaculum* gen. nov., a new genus in the Lachnospiraceae: characterization of *Lachnoanaerobaculum umeaense* gen. nov., sp. nov., isolated from the human small intestine, and *Lachnoanaerobaculum orale* sp. nov., isolated from saliva, and reclassification of *Eubacterium saburreum* (Prevot 1966) Holdeman and Moore 1970 as *Lachnoanaerobaculum saburreum* comb. nov. *Int J Syst Evol Microbiol* 62:2685–2690
- Ivanov II, Honda K (2012) Intestinal commensal microbes as immune modulators. *Cell Host Microbe* 12:496–508
- Kamilova AT, Akhmedov NN, Pulatova DB, Nurmatov BA (2001) Intestinal microbiocenosis in children with intestinal enzymopathy. *Zh Mikrobiol Epidemiol Immunobiol* 3:97–99
- Kopečný J, Mrázek J, Fliegerová K, Kott T (2006) Effect of gluten-free diet on microbes in the colon. *Folia Microbiol (Praha)* 51:287–290
- Kopečný J, Mrázek J, Fliegerová K, Frühauf P, Tucková L (2008) The intestinal microflora of childhood patients with indicated coeliac disease. *Folia Microbiol (Praha)* 53:214–216
- M'hir S, Rizzello CG, Di Cagno R, Cassone A, Hamdi M (2009) Use of selected enterococci and *Rhizopus oryzae* proteases to hydrolyse wheat proteins responsible for coeliac disease. *J Appl Microbiol* 106:421–431
- Medina M, De Palma G, Ribes-Koninckx C, Calabuig M, Sanz Y (2008) *Bifidobacterium* strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. *J Inflamm (Lond)* 5:19
- Moroni AV, Dal Bello F, Arendt EK (2009) Sourdough in gluten-free bread-making: an ancient technology to solve a novel issue? *Food Microbiol* 26:676–684
- Moroni AV, Arendt EK, Dal BF (2011) Biodiversity of lactic acid bacteria and yeasts in spontaneously-fermented buckwheat and teff sourdoughs. *Food Microbiol* 28:497–502
- Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2007) Imbalance in the composition of the duodenal microbiota of children with coeliac disease. *J Med Microbiol* 56:1669–1674
- Nistal E, Caminero A, Herrán AR, Arias L, Vivas S, de Morales JM, Calleja S, de Miera LE, Arroyo P, Casqueiro J (2012) Differences of small intestinal bacteria populations in adults and children with/without coeliac disease: effect of age, gluten diet, and disease. *Inflamm Bowel Dis* 18:649–656
- Rizzello CG, De Angelis M, Di Cagno R, Camarica A, Silano M, Losito I, De Vincenzi M, De Bari MD, Palmisano F, Maurano F, Gianfrani C, Gobbetti M (2007) Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for coeliac disease. *Appl Environ Microbiol* 73:4499–4507
- Rizzello CG, Coda R, De Angelis M, Di Cagno R, Carnevali P, Gobbetti M (2009) Long-term fungal inhibitory activity of water-soluble extract from *Amaranthus* spp. seeds during storage of gluten-free and wheat flour breads. *Int J Food Microbiol* 131:189–196
- Rollán G, De Angelis M, Gobbetti M, de Valdez GF (2005) Proteolytic activity and reduction of gliadin-like fractions by sourdough lactobacilli. *J Appl Microbiol* 99:1495–1502
- Rühmkorf C, Jungkunz S, Wagner M, Vogel RF (2012) Optimization of homoexopolysaccharide formation by lactobacilli in gluten-free sourdoughs. *Food Microbiol* 32:286–294
- Salvatore S, Hauser B, Devreker T, Arrigo S, Vandenplas Y (2008) Chronic enteropathy and feeding in children: an update. *Nutrition* 24:1205–1216
- Samaşca G, Sur G, Lupan I (2013) Current trends and investigative developments in coeliac disease. *Immunol Invest* 42:273–284
- Sánchez E, Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2008) Reduced diversity and increased virulence-gene carriage in intestinal enterobacteria of coeliac children. *BMC Gastroenterol* 8:50
- Sánchez E, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2010) Intestinal *Bacteroides* species associated with coeliac disease. *J Clin Pathol* 63:1105–1111
- Sánchez E, De Palma G, Capilla A, Nova E, Pozo T, Castillejo G, Varea V, Marcos A, Garrote JA, Polanco I, López A, Ribes-Koninckx C, García-Novo MD, Calvo C, Ortigosa L, Palau F, Sanz Y (2011)

- Influence of environmental and genetic factors linked to celiac disease risk on infant gut colonization by *Bacteroides* species. *Appl Environ Microbiol* 77:5316–5323
- Sánchez E, Laparra JM, Sanz Y (2012a) Discerning the role of *Bacteroides fragilis* in celiac disease pathogenesis. *Appl Environ Microbiol* 78:6507–6515
- Sánchez E, Ribes-Koninckx C, Calabuig M, Sanz Y (2012b) Intestinal *Staphylococcus* spp. and virulent features associated with coeliac disease. *J Clin Pathol* 65:830–834
- Sanz Y (2010) Effects of a gluten-free diet on gut microbiota and immune function in healthy adult humans. *Gut Microbes* 1:135–137
- Sanz Y, Sánchez E, Marzotto M, Calabuig M, Torriani S, Dellaglio F (2007) Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis. *FEMS Immunol Med Microbiol* 51:562–568
- Sanz Y, De Pama G, Laparra M (2011) Unraveling the ties between celiac disease and intestinal microbiota. *Int Rev Immunol* 30:207–218
- Schippa S, Iebba V, Barbato M, Di Nardo G, Totino V, Checchi MP, Longhi C, Maiella G, Cucchiara S, Conte MP (2010) A distinctive ‘microbial signature’ in celiac pediatric patients. *BMC Microbiol* 10:175
- Serban DE (2011) The gut microbiota in the metagenomics era: sometimes a friend, sometimes a foe. *Roum Arch Microbiol Immunol* 70:134–140
- Sun-Waterhouse D, Chen J, Chuah C, Wibisono R, Melton LD, Laing W, Ferguson LR, Skinner MA (2009) Kiwifruit-based polyphenols and related antioxidants for functional foods: kiwifruit extract-enhanced gluten-free bread. *Int J Food Sci Nutr* 60:251–264
- Tlaskalová-Hogenová H, Farré-Castany MA, Stěpánková R, Kozáková H, Tucková L, Funda DP, Barot R, Cukrowska B, Sinkora J, Mandel L, Karská K, Kolínská J (1995) The gut as a lymphoepithelial organ: the role of intestinal epithelial cells in mucosal immunity. *Folia Microbiol (Praha)* 40:385–391
- Zannini E, Jones JM, Renzetti S, Arendt EK (2012a) Functional replacements for gluten. *Annu Rev Food Sci Technol* 3:227–245
- Zannini E, Pontonio E, Waters DM, Arendt EK (2012b) Applications of microbial fermentations for production of gluten-free products and perspectives. *Appl Microbiol Biotechnol* 93:473–485